The role of myokines in cancer: crosstalk between skeletal muscle and tumor
暂无分享,去创建一个
[1] K. Dimas,et al. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC , 2023, Frontiers in Immunology.
[2] S. Yoon,et al. Sarcopenia in pancreatic cancer: Effect on patient outcomes , 2022, World journal of gastrointestinal oncology.
[3] Zhenwen Zhang,et al. Adipose–Muscle crosstalk in age-related metabolic disorders: The emerging roles of adipo-myokines , 2022, Ageing Research Reviews.
[4] Xiaoping Su,et al. Exercise-induced IL-15 acted as a positive prognostic implication and tumor-suppressed role in pan-cancer , 2022, Frontiers in Pharmacology.
[5] C. Diwoky,et al. Interleukin‐6 initiates muscle‐ and adipose tissue wasting in a novel C57BL/6 model of cancer‐associated cachexia , 2022, Journal of cachexia, sarcopenia and muscle.
[6] Qingshui Wang,et al. Low FNDC5/Irisin expression is associated with aggressive phenotypes in gastric cancer , 2022, Frontiers in Pharmacology.
[7] C. Isacke,et al. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment , 2022, The Journal of clinical investigation.
[8] Yong Xia,et al. Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. , 2022, Biochimica et biophysica acta. Reviews on cancer.
[9] Z. Wang,et al. Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21 , 2022, Medicine.
[10] B. Jena,et al. Understanding Brain-Skeletal Muscle Crosstalk Impacting Metabolism and Movement , 2022, Discoveries.
[11] T. He,et al. SPARC Overexpression Promotes Liver Cancer Cell Proliferation and Tumor Growth , 2021, Frontiers in Molecular Biosciences.
[12] R. Newton,et al. Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT , 2021, Medicine and science in sports and exercise.
[13] S. Lamon,et al. Mechanisms of chemotherapy‐induced muscle wasting in mice with cancer cachexia , 2021, JCSM Rapid Communications.
[14] H. Nikzad,et al. Effects of the exercise-inducible myokine irisin on proliferation and malignant properties of ovarian cancer cells through the HIF-1 α signaling pathway , 2021, bioRxiv.
[15] Pronoy K. Mondal,et al. Reciprocal interplay between asporin and decorin: Implications in gastric cancer prognosis , 2021, PloS one.
[16] Qiang Li,et al. Decorin Suppresses Invasion and EMT Phenotype of Glioma by Inducing Autophagy via c-Met/Akt/mTOR Axis , 2021, Frontiers in Oncology.
[17] T. Katsuno,et al. Effects of exercise intensity and duration on a myokine, secreted protein acidic and rich in cysteine , 2021, European journal of sport science.
[18] R. Newton,et al. Exercise-induced myokines and their effect on prostate cancer , 2021, Nature Reviews Urology.
[19] D. Serra,et al. Hypothalamus-skeletal muscle crosstalk during exercise and its role in metabolism modulation. , 2021, Biochemical pharmacology.
[20] Jianwen Hu,et al. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis. , 2021, Biochemical and biophysical research communications.
[21] Xiufen Jia,et al. SPARC promotes pancreatic cancer cell proliferation and migration through autocrine secretion into the extracellular milieu , 2021, Oncology letters.
[22] T. Zimmers,et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia , 2021, The Journal of experimental medicine.
[23] W. Woodward,et al. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer , 2021, Communications biology.
[24] K. Simon,et al. Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma , 2020, Clinical and experimental hepatology.
[25] chiun-wei Huang,et al. Irisin, an exercise myokine, potently suppresses tumor proliferation, invasion, and growth in glioma , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] B. Pedersen,et al. Muscle–Organ Crosstalk: The Emerging Roles of Myokines , 2020, Endocrine reviews.
[27] N. Tinari,et al. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study , 2020, Scientific Reports.
[28] M. Esawy,et al. The diagnostic and prognostic roles of serum irisin in bladder cancer. , 2019, Current problems in cancer.
[29] Qiang Li,et al. Erlotinib inhibits colon cancer metastasis through inactivation of TrkB‐dependent ERK signaling pathway , 2019, Journal of cellular biochemistry.
[30] F. Greten,et al. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.
[31] C. Friedenreich,et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review , 2019, Medicine and science in sports and exercise.
[32] R. Weinberg,et al. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities , 2018, Frontiers of Medicine.
[33] M. Korc,et al. Cancer-associated cachexia , 2018, Nature Reviews Disease Primers.
[34] C. Weigert,et al. Skeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations. , 2017, Cold Spring Harbor perspectives in medicine.
[35] E. Miyamoto-Mikami,et al. A Mechanism Underlying Preventive Effect of High-Intensity Training on Colon Cancer , 2017, Medicine and science in sports and exercise.
[36] Hui Li,et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. , 2017, Biochemical and biophysical research communications.
[37] M. Jackson,et al. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer , 2017, Molecular Cancer Research.
[38] S. Chiou,et al. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings , 2016, Oncotarget.
[39] N. Coleman,et al. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial–mesenchymal transition and poor overall survival , 2016, British Journal of Cancer.
[40] A. Fournier,et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. , 2016, JAMA internal medicine.
[41] A. Šimundić,et al. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer—chemotherapy toxicity and prognostic value , 2016, Supportive Care in Cancer.
[42] M. Caligiuri,et al. Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype , 2016, Cancer Immunology Research.
[43] X. Qiu,et al. More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells , 2016, BMC Cancer.
[44] Undurti N. Das,et al. Brain-derived neurotrophic factor and its clinical implications , 2015, Archives of medical science : AMS.
[45] Y. Naito,et al. Tumor inoculation site affects the development of cancer cachexia and muscle wasting , 2015, International journal of cancer.
[46] G. Georgiou,et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics , 2015, BMC Cancer.
[47] R. Iozzo,et al. Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. , 2015, Biochemistry.
[48] F. López‐Soriano,et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. , 2015, Current opinion in pharmacology.
[49] V. Prod’homme,et al. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis , 2015, Nature Communications.
[50] Alessandro Rosa,et al. Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice , 2015, Nature Communications.
[51] W. Frontera,et al. Skeletal Muscle: A Brief Review of Structure and Function , 2015, Calcified Tissue International.
[52] M. Bisoffi,et al. Effects of the exercise‐inducible myokine irisin on malignant and non‐malignant breast epithelial cell behavior in vitro , 2015, International journal of cancer.
[53] Derya Demirtas,et al. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia , 2015, Medical Oncology.
[54] James A. Nathan,et al. Muscle wasting in disease: molecular mechanisms and promising therapies , 2014, Nature Reviews Drug Discovery.
[55] C. Vanhove,et al. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. , 2014, Cancer research.
[56] Jianguo Feng,et al. SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target. , 2014, Current pharmaceutical design.
[57] A. Schürmann,et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. , 2014, Biochemical and biophysical research communications.
[58] L. Chirieac,et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis , 2014, Proceedings of the National Academy of Sciences.
[59] M. Bhatt,et al. Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin , 2014, Oncotarget.
[60] Jose M Garcia,et al. Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review , 2014, Gerontology.
[61] C. Richards. The Enigmatic Cytokine Oncostatin M and Roles in Disease , 2013, ISRN inflammation.
[62] J. Minna,et al. A Novel Molecular Pathway for Snail-Dependent, SPARC-Mediated Invasion in Non–Small Cell Lung Cancer Pathogenesis , 2013, Cancer Prevention Research.
[63] M. Kjaer,et al. Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise , 2013, Scandinavian journal of medicine & science in sports.
[64] Mary T. Brinkoetter,et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. , 2012, Metabolism: clinical and experimental.
[65] O. Lee,et al. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. , 2012, Cancer research.
[66] Wei Wang,et al. Secreted Protein Acidic and Rich in Cysteine (SPARC) Suppresses Angiogenesis by Down-Regulating the Expression of VEGF and MMP-7 in Gastric Cancer , 2012, PloS one.
[67] Y. Naito,et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise , 2012, Gut.
[68] Jose M Garcia,et al. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers , 2012, Journal of cachexia, sarcopenia and muscle.
[69] M. Febbraio,et al. Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.
[70] Wancai Yang,et al. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. , 2012, Carcinogenesis.
[71] I. Tai,et al. A Peptide of SPARC Interferes with the Interaction between Caspase8 and Bcl2 to Resensitize Chemoresistant Tumors and Enhance Their Regression In Vivo , 2011, PloS one.
[72] B. Pedersen,et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. , 2011, American journal of physiology. Endocrinology and metabolism.
[73] M. Kaneki,et al. Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? , 2011, Endocrine journal.
[74] G. Corazza,et al. Role of IL-15 in immune-mediated and infectious diseases. , 2011, Cytokine & growth factor reviews.
[75] R. Iozzo,et al. Decorin Antagonizes Met Receptor Activity and Down-regulates β-Catenin and Myc Levels* , 2010, The Journal of Biological Chemistry.
[76] B. Jasmin,et al. Brain-derived Neurotrophic Factor Regulates Satellite Cell Differentiation and Skeltal Muscle Regeneration , 2010, Molecular biology of the cell.
[77] M. During,et al. Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition , 2010, Cell.
[78] H. Frierson,et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression , 2009, Oncogene.
[79] M. Febbraio,et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase , 2009, Diabetologia.
[80] B. Pedersen,et al. Expression of interleukin‐15 in human skeletal muscle – effect of exercise and muscle fibre type composition , 2007, The Journal of physiology.
[81] L. Hengst,et al. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. , 2006, Cancer research.
[82] R. Iozzo,et al. Decorin prevents metastatic spreading of breast cancer , 2005, Oncogene.
[83] R. Ferrell,et al. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. , 2004, Journal of applied physiology.
[84] E Helene Sage,et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. , 2004, Molecular cancer research : MCR.
[85] R. Brekken,et al. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.
[86] N. Lemke,et al. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.
[87] Roland R Roy,et al. Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. , 2002, Journal of neurophysiology.
[88] R. Iozzo,et al. Decorin suppresses tumor cell-mediated angiogenesis , 2002, Oncogene.
[89] C. Begley,et al. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells , 2002, Oncogene.
[90] E. Sage,et al. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.
[91] K. Syrigos,et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. , 2001, Anticancer research.
[92] H. Halfter,et al. Complete inhibition of in vivo glioma growth by oncostatin M , 2001, Journal of neurochemistry.
[93] B. Ruggeri,et al. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on In vitro invasive behavior , 1999, International journal of cancer.
[94] B. Bonavida,et al. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.
[95] Jonathan M. Harris,et al. Mobilizing serum factors and immune cells through exercise to counteract age-related changes in cancer risk. , 2020, Exercise immunology review.
[96] M. Götte,et al. More than matrix: the multifaceted role of decorin in cancer. , 2013, European journal of cell biology.
[97] F. Tarantini,et al. Skeletal muscle: an endocrine organ. , 2013, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[98] M. Ruth. A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis , 2012 .
[99] B. Dréno,et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. , 2007, Oncogene.
[100] Peter H Watson,et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[101] T. Okusaka,et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. , 1998, Japanese journal of clinical oncology.